Abstract
We have selected a well-characterized human renal cell carcinoma (RCC) line as the basis for development of a genetically engineered tumor cell vaccine to be applied in an allogeneic setting. This cell line was genetically modified by retroviral transduction to express B7.1 costimulatory molecules. The unmodified tumor cells and B7.1-expressing tumor cells were compared for their ability to induce tumor-associated responses in allogeneic peripheral blood mononuclear cells (PBMC) of two normal control donors having single MHC class I allele matches with the tumor cells. PBMC primed using B7.1-modified tumor cells showed a preponderance of CD3+CD8+ cytotoxic T lymphocytes (CTL) that proliferated over extended periods of time in mixed lymphocyte tumor cell (MLTC) cultures. Strong cytolytic activity developed in the primed populations and included allospecific CTL with specificity for mismatched HLA-A, -B and -C molecules. Nevertheless, it was possible to isolate CTL clones that were able to lyse tumor cells but not lymphoblastoid cells that expressed all the corresponding allospecificities. Thus, induction of complex allospecific responses did not hinder the development of tumor-associated CTL in vitro. These results support the use of this genetically modified allogeneic tumor cell line for vaccination of partial-MHC matched RCC patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Noessner E, Schendel DJ . Autologous and allogeneic tumor cell vaccines. In: Blankenstein Th (ed) Gene Therapy, Principles and Applications1 Birkhäuser Verlag: Basel 1999 299–312
Hui K, Grosveld F, Festenstein H . Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation Nature 1984 311: 750–752
Hui KM, Sim T, Foo TT, Oei AA . Tumor rejection mediated by transfection with allogeneic class I histocompatibility gene J Immunol 1989 143: 3835–3843
Nabel GJ, Felgner PL . Direct gene transfer for immunotherapy and immunization Trends Biotechnol 1993 11: 211–215
Kayaga J et al. Anti-tumor activity against B16F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine Gene Therapy 1999 6: 1475–1481
Toes REM et al. Protective antitumor immunity induced by immunization with completely allogeneic tumor cells Cancer Res 1996 56: 3782–3787
Mandelboim O, Vadai E, Feldman M, Eisenbach L . Expression of two H-2K genes, syngeneic and allogeneic, as a strategy for potentiating immune recognition of tumor cells Gene Therapy 1995 2: 757–765
Schendel DJ et al. Tumor-specific lysis of human renal cell carcinomas by tumor- nfiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines J Immunol 1993 151: 4209–4220
Jantzer P, Schendel DJ . Human renal cell carcinoma antigen-specific cytotoxic T lymphocytes: antigen-driven selection and long-term persistence in vivo Cancer Res 1998 58: 3078–3086
Schendel DJ et al. Cellular and molecular analyses of MHC-restricted and non-MHC-restricted effector cells recognizing renal cell carcinomas: problems and perspectives for immunotherapy J Mol Med 1997 75: 400–413
Chen L et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 Cell 1992 71: 1093–1102
Townsend SE, Allison JP . Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells (see comments) Science 1993 259: 368–370
Li Y, McGowan P, Hellström KE, Chen L . Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma J Immunol 1994 153: 421–428
Hellstrom KE, Hellstrom I, Chen L . Can co-stimulated tumor immunity be therapeutically efficacious? Immunol Rev 1995 145: 123–145
Johnston JV et al. B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes J Exp Med 1996 183: 791–800
Martin-Fontecha A et al. Heterogeneous effects of B7–1 and B7–2 in the induction of both protective and therapeutic antitumor immunity against different mouse tumors Eur J Immunol 1996 26: 1851–1859
Leong CC et al. Transfection of the gene for B7–1 but not B7–2 can induce immunity to murine malignant mesothelioma Int J Cancer 1997 71: 476–482
Hodge JW, Abrams S, Schlom J, Kantor JA . Induction of antitumor immunity by recombinant vaccinia viruses expressing B7–1 or B7–2 costimulatory molecules Cancer Res 1994 54: 5552–5555
Sulé-Suso J et al. A B7–1-transfected human melanoma line stimulates proliferation and cytotoxicity of autologous and allogeneic lymphocytes Eur J Immunol 1995 25: 2737–2742
Antonia SJ et al. B7–1 expression by a non-antigen presenting cell-derived tumor Cancer Res 1995 55: 2253–2256
Bain C et al. B7.1 gene transduction of human renal-cell-carcinoma cell lines restores the proliferative response and cytotoxic function of allogeneic T cells Int J Cancer 1996 67: 769–776
Wang YC et al. Induction of autologous tumor-specific cytotoxic T-lymphocyte activity against a human renal carcinoma cell line by B7–1 (CD80) costimulation J Immunother Emphasis Tumor Immunol 1996 19: 1–8
Yang SX et al. Generation of primary tumor-specific cytotoxic T lymphocytes from autologous and human lymphocyte antigen class I-matched allogeneic peripheral blood lymphocytes by B7 gene-modified melanoma cells Cancer Res 1997 57: 1561–1568
Hirano N et al. Protective and therapeutic immunity against leukemia induced by irradiated B7–1 (CD80)-transduced leukemic cells Hum Gene Ther 1997 8: 1375–1384
Jung D et al. Strong immunogenic potential of a B7 retroviral expression vector: generation of HLA-B7-restricted CTL response against selectable marker genes Hum Gene Ther 1998 9: 53–62
Motzer RJ, Bander NH, Nanus DM . Renal cell carcinoma New Engl J Med 1996 335: 865–875
Boon T, Coulie PG, Van den Eynde B . Tumor antigens recognized by T cells Immunol Today 1997 18: 267–268
Panelli MC et al. A tumor-infiltrating lymphocyte for a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12 J Immunol 2000 164: 4382–4392
Moebius U et al. Expression of different CD8 isoforms on distinct human lymphocyte subpopulations Eur J Immunol 1991 21: 1793–1800
Döhring C, Angman L, Spagnoli G, Lanzavecchia A . T-helper and accessory cell independent cytotoxic responses to human tumor cells transfected with a B7 retroviral vector Int J Cancer 1994 57: 754–759
Ramarathinam L, Castle M, Wu Y, Liu Y . T cell costimulation with B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells J Exp Med 1994 179: 1205–1214
Fenton RG, Turcovski-Corrales SM, Taub DD . Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines J Immunother 1998 21: 95–108
Imro MA et al. Human melanoma cells transfected with the B7–2 co-stimulatory molecule induce tumor-specific CD8+ cytotoxic T lymphocytes in vitro Hum Gene Ther 1998 9: 1335–1344
Meuer SC et al. Construction of immunogenic tumor cell surfaces by somatic gene transfer Recent Results Cancer Res 1998 144: 78–85
Meyer GC et al. Potential of CD80-transfected human breast carcinoma cells to induce peptide-specific T lymphocytes in an allogeneic human histocompatibility leukocyte antigen (HLA)-A2.1+-matched situation Cancer Gene Ther 1999 6: 282–288
Meyer GC et al. Induction of antigen-specific T cells by allogeneic CD80 transfected human carcinoma cells Adv Exp Med Biol 1998 451: 195–202
Schendel DJ, Maget B, Falk CS, Wank R . Human CD8+ T lymphocytes. In: Lefkovits I (ed) The Immunology Methods Manual Academic Press: London 1997 670–690
Köhler I et al. Human interleukin-13 activates the interleukin-4-dependent transcription factor NF-IL-4 sharing a DNA binding motif with an interferon-gamma induced nuclear binding factor FEBS Lett 1994 345: 187–192
Daniel PT et al. Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis J Immunol 1997 159: 3808–3815
Schendel DJ, Wank R, Dupont B . Standardization of the human in vitro cell-mediated lympholysis technique Tissue Antigens 1979 13: 112–120
Acknowledgements
This work was supported by grants of the Deutsche Forschungsgemeinschaft (Ho 1596/3–2) and the Bundesministerium für Bildung, Forschung und Technologie (01GE9624, 01KV9506, and 01EC9406). We thank S Lupton for the vector tgls(+) HyTK and A Gärtner for excellent technical support.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schendel, D., Frankenberger, B., Jantzer, P. et al. Expression of B7.1 (CD80) in a renal cell carcinoma line allows expansion of tumor-associated cytotoxic T lymphocytes in the presence of an alloresponse. Gene Ther 7, 2007–2014 (2000). https://doi.org/10.1038/sj.gt.3301349
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3301349
Keywords
This article is cited by
-
Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study
Gene Therapy (2011)
-
GPI-anchored TIMP-1 treatment renders renal cell carcinoma sensitive to FAS-meditated killing
Oncogene (2006)
-
An immune edited tumour versus a tumour edited immune system: prospects for immune therapy of acute myeloid leukaemia
Cancer Immunology, Immunotherapy (2006)
-
A generic RNA-pulsed dendritic cell vaccine strategy for renal cell carcinoma
Journal of Translational Medicine (2005)
-
A CD80-transfected human breast cancer cell variant induces HER-2/neu?specific T cells in HLA-A*02?matched situations in vitro as well as in vivo
Cancer Immunology, Immunotherapy (2005)